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Abstract
Hereditary factors are presumed to play a role in one third of colorectal cancer (CRC) cases. However, in the majority of
familial CRC cases the genetic basis of predisposition remains unexplained. This is particularly true for families with few
affected individuals. To identify susceptibility genes for this common phenotype, we examined familial cases derived from a
consecutive series of 1514 Finnish CRC patients. Ninety-six familial CRC patients with no previous diagnosis of a hereditary
CRC syndrome were included in the analysis. Eighty-six patients had one affected first-degree relative, and ten patients had
two or more. Exome sequencing was utilized to search for genes harboring putative loss-of-function variants, because such
alterations are likely candidates for disease-causing mutations. Eleven genes with rare truncating variants in two or three
familial CRC cases were identified: UACA, SFXN4, TWSG1, PSPH, NUDT7, ZNF490, PRSS37, CCDC18, PRADC1, MRPL3, and
AKR1C4. Loss of heterozygosity was examined in all respective cancer samples, and was detected in seven occasions
involving four of the candidate genes. In all seven occasions the wild-type allele was lost (P= 0.0078) providing additional
evidence that these eleven genes are likely to include true culprits. The study provides a set of candidate predisposition
genes which may explain a subset of common familial CRC. Additional genetic validation in other populations is required to
provide firm evidence for causality, as well as to characterize the natural history of the respective phenotypes.
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Introduction
Colorectal cancer (CRC) (MIM 114500) is a major cancer type,
with over one million new cases diagnosed worldwide each year. It
is the third most common malignancy [1], and the second most
common cause of cancer mortality [2]. Inherited factors are
estimated to play a crucial role in at least one third of all CRC
cases [3]. However, high-penetrance mutations in known CRC
predisposing genes, such as the mismatch repair (MMR) genes,
APC, MUTYH (MYH), SMAD4, BMPR1A, STK11/LKB1, PTEN,
AXIN2, POLE, and POLD1 explain only around 5% of these cases
[4–6].
There are a few examples of rare variants in CRC predisposing
genes conferring moderate or low carrier risk, such as APC
(I1307K) [7], BLM [8] and GALNT12 [9]. Of these, the APC
I1307K variant has been most extensively studied and occurs
almost exclusively in the Ashkenazi Jewish population [7]. In
addition to these, genome-wide association (GWA) studies have
identified common low-penetrance variants at approximately 20
genomic loci associated with CRC susceptibility. However, the
identified common variants at these loci exert only a modest effect
on CRC risk [10–12].
Unknown variants of moderate or low penetrance are likely to
explain at least part of the missing heritability in CRC. CRC
families with few affected individuals are an attractive patient
group to search for such genetic factors, but tools for such work
have been poor. These families are relatively common but too
small for linkage analyses, and the culprit variants are likely to be
too diverse and rare to be detected in GWA studies. One approach
has been to study the additive contribution of low-penetrance
variants on familial risk. A previous study has estimated that ten
known low-penetrance CRC variants collectively explain around
9% of the variance in familial risk [13]. Advances in sequencing
technologies have made exome sequencing a feasible approach to
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search for rare coding variants of varying penetrance. In this
study, we aimed at identifying variants predisposing to common
familial CRC by performing exome sequencing on 96 indepen-
dent familial CRC cases derived from a consecutive collection of
unselected patients. Here, familial CRC is characterized as
having at least one first-degree relative diagnosed with CRC;
indeed the great majority of the 96 familial cases displayed only
one first-degree relative with CRC. All patients were from
Finland, known for its relatively homogenous population
[14,15]. This empowers the analysis since affected individuals
are more likely to share ancestral predisposition mutations and
haplotypes, stemming from a handful of founders. To our
knowledge, this is the largest effort to date where exome
sequencing has been applied to familial forms of cancer to
identify novel predisposing genes.
Results
Exome sequencing
Exome sequencing analysis was performed on germline DNA
from 96 independent familial CRC cases. The clinical and
histopathological features of the cases are summarized in Table 1
and in more detail in Table S1. The average read depth attained
for target regions was 43 and at least 86% of the captured target
regions were covered by four or more sequence reads for all the
samples. We identified a total of 76,487 nonsynonymous variants
in the exome data (Figure 1). Sequence data were first evaluated
for known predisposing genes (MLH1, MSH2, MSH6, PMS2, APC,
MUTYH, SMAD4, BMPR1A, LKB1/STK11, PTEN, AXIN2, POLE,
and POLD1). No clear pathogenic mutations were found in these
genes. The following missense variants were identified (not
confirmed by Sanger sequencing); MSH6 c.2800G.C p.D934H,
and PTEN c.1016C.A P339Q. However, the patients did not
present typical clinical phenotypes; in the case of the MSH6
variant the tumor did not display microsatellite instability and in
the case of the PTEN variant patient records revealed no features
suggestive of Cowden syndrome (MIM 158350). Thus, these
variants remain of unknown clinical significance.
Identification of colorectal cancer predisposing variants
We hypothesized that predisposing germline variants would
likely be rare in the general population, and predicted to truncate
the protein product. We therefore filtered the data to prioritize
such variants (Figure 1). First, variants had to be protein truncating
with putative loss-of-function alteration; including nonsense,
frameshift (insertion and deletion) or splice-site variants (IVS +1,
+2, 21, and 22). A total number of 3,654 truncating variants
were found in the exome data. Second, variants were excluded if
present in the 1000 Genomes Project [16] or population matched
exome control data (n = 212) at minor allele frequency
(MAF).0.001. After control filtering, 2,090 truncating variants
remained. Third, genes with truncating variants in more than one
familial CRC case were selected for further analysis. There were a
total of 588 such variants of which 422 were frameshift, 115
nonsense, and 51 splice site variants (Figure 1). Frameshift variants
were grossly overrepresented in the list of truncating variants due
to sequencing artifacts. Finally, manual filtering was performed on
all variants to further remove artifacts due to duplicated regions,
mapping errors, and systematic sequence specific errors. The
filtering procedure resulted in a shortlist of 29 genes with 46
truncating variants. These were subsequently validated by Sanger
sequencing (Figure 1).
Sanger sequencing was successful for all amplicons, and 23
truncating variants in 18 genes were confirmed. Of these seven
were frameshift, 12 nonsense, and four splice-site variants. To
Author Summary
Many individuals with a family history of colorectal cancer
have no detectable germline mutation in the known
cancer predisposing genes. We aimed to identify novel
susceptibility genes for this common phenotype by
performing exome sequencing on 96 independent cases
with familial colorectal cancer. Eighty-six patients had one
affected first-degree relative, and ten patients had two or
more. None of the patients had a previous diagnosis of a
hereditary syndrome. We focused our search on genes
with rare variants, predicted to truncate the protein
product, since these are likely candidates for disease
predisposition. Using this approach we identified truncat-
ing germline variants in eleven genes, present in two or
three independent familial colorectal cancer cases. We
analyzed the respective tumor DNAs and found loss of the
wild-type allele in seven out of seven occasions, involving
four genes. No tumor showed loss of the mutant allele
which provides us with additional evidence for disease
causality. Further studies are required to provide firm
evidence for pathogenicity. Genetic knowledge on con-
firmed predisposing genes can ultimately be translated
into tools for cancer prevention and early diagnosis in
individuals carrying predisposition alleles.
Table 1. Clinical characteristics of the 96 cases with familial
colorectal cancer.
Characteristics
Mean (SD) Range
Age, mean (SD) 70 (11) 32–90
Count (%)
Gender
Female 45 47%
Male 51 53%
First degree relatives with CRC
1 86 90%
2 8 8%
3–4 2 2%
MSI status
MSS 88 92%
MSI 8 8%
Dukes stage
A–B 61 64%
C–D 34 35%
Histologic grade
1–2 81 84%
3–4 11 11%
Location*
Distal 59 61%
Proximal 36 38%
NOTE: some of the numbers do not match due to missing data.
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable.
*Distal, from splenic flexure to rectum; proximal, from cecum to transverse
colon.
doi:10.1371/journal.pgen.1003876.t001
Novel Susceptibility Genes for Colorectal Cancer
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further exclude neutral polymorphisms, the confirmed variants
were screened in 310 Finnish population matched controls, of
which approximately two-thirds were also regionally matched.
Variants with MAF.0.001 in the overall discovery phase control
set (including Finnish control exome data and Sanger sequenced
controls) were excluded (Figure 1).
In total, we identified 11 candidate predisposing genes with 14
truncating germline variants in at least two familial CRC cases
(Table 2); UACA, SFXN4, TWSG1, PSPH, NUDT7, ZNF490,
PRSS37, CCDC18, PRADC1, MRPL3, and AKR1C4. A summary of
all these variants and respective frequencies are presented in
Table 2. Gene descriptions and proposed functions of the
identified genes are listed in Table S2. Typically, the same
truncating variant was detected in several patients. However, three
genes harbored two different types of truncating germline variants
(Table 2). Nine genes showed truncating variants in 2/96 familial
cases. Two genes had truncating variants in 3/96 cases; UACA
(uveal autoantigen with coiled-coil domains and ankyrin repeats) (3/96,
3.1%) and SFXN4 (sideroflexin 4) (3/96, 3.1%). In UACA,
p.Q1116X was identified in two out of 96 familial cases and
present in 522 Finnish population matched controls with a MAF of
0.001. UACA p.R1292X was found in one out of 96 cases and the
variant was not found in controls (Figure 2). In SFXN4, three out of
96 cases had c.32delC. This variant had a MAF of 0.001 in
population matched controls. None of the other identified
truncating variants were identified in population matched controls,
except for c.389_390insA in PSPH which was found in 1/502
controls (MAF 0.001). To further explore the frequency of these
variants in controls, we referred to the Exome Variant Server
(NHLBI GO Exome Sequencing Project (ESP), Seattle, WA,
http://evs.gs.washington.edu/EVS/ [July 2013]). Three of the
identified germline variants, SFXN4 c.32delC, NUDT7 c.111T.A,
and PRSS37 c.176+1G.A, were reported, however, at a MAF of
less than 0.0003.
The exome data was also searched for missense variants in the
11 candidate predisposition genes; five missense variants were
observed in five genes (Table S3). All of the missense variants were
present in one case only, except for p.Q83H in PSPH which was
identified in two out of the 96 familial cases. None of the missense
variants were predicted to have a damaging effect on the protein
by either of the prediction programs used (Table S3). The
identified missense variants were very rare in population matched
controls (MAF,0.001).
Loss of heterozygosity analysis
Loss of heterozygosity (LOH) was examined in cancers of CRC
cases with candidate predisposing germline variants (Figure 1).
The following genes displayed LOH in at least one cancer: UACA,
TWSG1, PSPH, and ZNF490 (Table 2). Seven LOH events were
observed and all targeted the wild-type allele (P=0.0078). In
UACA three out of six examined tumors showed loss of the wild-
type allele and in TWSG1 (twisted gastrulation protein homolog 1) both
of the tumors showed loss of the wild-type allele (Figure 2).
Genotyping population matched cases and controls
Variants in genes showing loss of the wild-type allele in tumor
tissue were genotyped in an independent set of validation phase
samples (Figure 1). This set included 954 Finnish population
matched CRC cases and 586 Finnish population matched
controls. UACA p.Q1116X was identified in two additional
unrelated CRC cases and one control (Table 2). The ages at
diagnosis were 67 and 58 years for the two cases. In the overall set
of Finnish population matched controls used in this study, two out
of 1,108 controls had UACA p.Q1116X (MAF=0.0009). UACA
p.R1292X was found in one additional case (diagnosis at the age
of 61) and no controls were heterozygous for this variant. The
variant p.R350X in ZNF490 was found in one additional case
(diagnosed at the age of 58) and remained absent in controls
(Table 2). TWSG1 p.Q41X was not present in any additional cases
or controls. Genotyping was not successful for PSPH
Figure 1. Schematic representation of the overall study design.
We performed exome sequencing analysis of germline DNA from 96
independent familial CRC cases. Initially, quality, frequency and control
filtering were applied to the exome data. Next, genes with putative
truncating loss-of-function variants in at least 2/96 cases were validated
by Sanger sequencing. Confirmed truncating variants were then
screened in Finnish population matched controls. Loss of heterozygos-
ity was analyzed in the respective tumor tissues. Variants in genes
showing loss of the wild-type allele in tumor tissue were genotyped in a
set of validation phase samples. Overall, 11 novel candidate CRC
predisposing genes were identified. CRC, colorectal cancer; MAF, minor
allele frequency; LOH, loss of heterozygosity.
doi:10.1371/journal.pgen.1003876.g001
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c.389_390insA. Next, LOH was analyzed in the tumors of the four
additional cases with truncating variants (Table 2). One of the
additional cases with UACA p.Q1116X showed LOH involving the
wild-type allele (Figure 2).
Segregation
Segregation analysis of the identified truncating variants was
performed for all the affected first degree relatives for whom
samples were available. In total, segregation was analyzed in seven
families for five of the identified truncating variants; c.32delC in
SFXN4, p.Q41X in TWSG1, p.R350X in ZNF490, c.168+1G.A
in PRADC1, and c.620delA in AKR1C4 (Figure 3 and Figure S1).
The following variants showed segregation; c.32delC in SFXN4,
c.168+1G.A in PRADC1, and c.620delA in AKR1C4. The variant
p.Q41X in TWSG1 segregated in one family but not the other
(Figure 3) and p.R350X in ZNF490 did not segregate (Figure S1).
Discussion
Exome sequencing is a powerful tool for discovering novel
genetic variants that predispose to disease [17]. To examine the
genetic basis of common familial CRC we exome sequenced 96
independent cases (Table 1) derived from a previously described
population-based collection of patients [4,18] and from an
additional unselected collection (unpublished). To our knowledge,
this is the largest effort to date where familial CRC has been
studied by exome sequencing to identify novel CRC predisposing
genes. Several strategies were applied to improve the power of
gene discovery. First, a large set of familial CRC cases (at least one
first-degree relative diagnosed with CRC) was utilized, negative for
any known high penetrance CRC mutation. Second, the cases
were from Finland, known for its isolated population with reduced
genetic heterogeneity. Such isolated populations are enriched for
rare founder variants, facilitating identification of disease genes
[15]. Third, tumor tissue availability for all the CRC cases allowed
for the assessment of somatic allelic imbalance, which gave
important additional information related to pathogenicity of the
variants. Fourth, genotyping of selected variants was performed in
a set of validation phase population matched samples, consisting of
954 cases and 586 controls.
In total, we identified 11 novel candidate CRC susceptibility
genes with rare truncating variants in two or three familial CRC
cases; UACA, SFXN4, TWSG1, PSPH, NUDT7, ZNF490, PRSS37,
CCDC18, PRADC1, MRPL3, and AKR1C4 (Table 2 and Table S2).
They were absent or rare (MAF#0.001) in the general population.
The results fit with the ‘‘rare variant hypothesis’’ that proposes
that a significant proportion of the missing heritability of complex
diseases is due to a series of rare variants, each conferring a
moderate increase in risk. Typically, such risk alleles function
dominantly and independently [19,20]. The ‘‘rare variant
hypothesis’’ is strongly supported by evolutionary theory, which
argues that variants that promote disease are selected against and
are therefore rare. Another argument for the hypothesis comes
from recent empirical population genetic data which shows that
rare variants are enriched for deleterious mutations [21]. The
question remains whether the identified candidate genes act as
classical tumor suppressors with second hits or show alternative
characteristics, such as haploinsufficiency or dominant-negative
effects. Of the genes identified, four out of 11 showed loss of the
wild-type allele in at least one tumor. In total, seven LOH events
were observed and none showed loss of the mutant allele
(P=0.0078). This suggests that complete inactivation of these
genes seems to be preferentially selected for in tumor evolution
and that these germline variants are prime candidates for CRC
susceptibility.
Perhaps the strongest candidate predisposition gene, in view of
the LOH data and case frequency, was the apoptosis-associated
gene UACA. Three of the 96 familial CRC cases were found to
carry heterozygous truncating variants (p.Q1116X and
p.R1292X) in UACA (Table 2). We performed genotyping to
screen the variants in a set of validation phase samples. We
identified three additional unrelated cases who were heterozygous
for the variants encoding either p.Q1116X or p.R1292X. Second
hits by LOH involving the germline wild-type allele were found in
three of the six tumors (Figure 2). The average age of onset of
CRC in the familial cases was 54 years (58, 54 and 50) (Figure 3),
younger than the mean age of onset of 71 in familial cases without
the UACA truncating variants (Table S1). UACA has recently been
identified as a novel regulator of apoptosis. It is known to reside
within the Apaf-1/procaspase-9 complex and regulate apoptosis
activating factor (APAF-1). It also regulates the apoptotic pathway
by controlling the activation of nuclear factor (NF)-kB [22]. In
addition, UACA gene expression has been shown to be down-
regulated in non-small cell lung carcinoma (MIM 211980) [23].
Taken together, the loss of UACA in cancer cells might result in
altered activation of apoptotic pathways, ultimately promoting
genesis of CRC.
Another gene of particular interest was TWSG1. The detected
truncating germline variant (p.Q41X) was present in two familial
CRC cases (2/96 cases) and completely absent in 1,039 Finnish
population matched controls (Table 2). Loss of the remaining
normal TWSG1 allele was observed in both tumors indicating that
the gene might act as a classical tumor suppressor gene (Figure 2).
The index case with Q41X in family 1 developed CRC at the age
of 53 and segregation analysis showed that the variant was
inherited from the affected mother (Figure 3). The mother had
developed CRC at the age of 68 and lung cancer at the age of 77.
The variant did not segregate with CRC in family 2. Rare risk
alleles of moderate penetrance are usually over-represented in
familial cases; however co-segregation of disease is not always
observed [19]. Previous studies have shown TWSG1 to be a
regulator of BMP-signaling [24]. It is known to act downstream of
TGF-b, inducing SMAD2 phosphorylation and mediating DNA
binding on Smad3/4 consensus sites [25]. TWSG1 functions in
cellular pathways that are essential in genesis of CRC, however, its
exact role in these pathways remains to be clarified.
In summary, exome sequencing is a well-justified strategy for
discovering cancer predisposing variants. The identification of
predisposing variants has substantial implications for disease risk
assessment and surveillance in family members. Here, we
identified eleven candidate predisposing genes with truncating
variations in familial CRC. A key challenge is how to identify
predisposing variants in the background of non-pathogenic
polymorphisms. Screening the eleven genes in familial CRC cases
representing different populations will be important to gain robust
evidence for pathogenicity, as well as to characterize the natural
history of the respective phenotypes. This information, then, can
be translated into tools for cancer prevention and early diagnosis
in individuals carrying true predisposition alleles.
Materials and Methods
Samples
This study was reviewed and approved by the Ethics Committee
of the Hospital district of Helsinki and Uusimaa (HUS). Signed
informed consent or authorization from the National Supervisory
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Authority for Welfare and Health was obtained for all the study
participants.
Discovery phase samples. A population-based material of
normal and tumor tissue from 1,042 CRC patients was collected
between 1994 and 1998 from nine Finnish central hospitals [4,18].
After 1998 sample collection continued from two of the nine
hospitals (unpublished collection). From the additional series 472
CRCs and respective normal tissue samples were available. From
these materials, familial CRC cases were selected according to the
following criteria: (i) at least one CRC case in a first degree
relative, (ii) negative for any known high penetrance CRC
mutation, and (iii) availability of sufficient amount of DNA
extracted from normal tissue (Figure 1). As part of previous efforts
[4,18], all cases had been tested for MSI, and in positive cases
Sanger sequencing of MLH1 and MSH2 had been performed.
Known polyposis syndromes could be excluded for all the familial
cases based on medical and pathological reports. In total, 96
familial cases fulfilled the above mentioned criteria. Clinical
characteristics are presented in Table 1 and in more detail in
Table S1. Both germline DNA extracted from blood or normal
colonic tissue and corresponding fresh-frozen tumour DNA were
available. Information on histological tumor grade and Dukes
stage was obtained from pathology reports. The discovery phase
control set compromised the following non-overlapping collec-
tions; in-house Finnish population matched control exome data
(n = 212) and DNA samples (n = 310) from population matched
healthy individuals obtained from the Finnish Red Cross Blood
Transfusion Service. Around two-thirds of the control DNA
samples were regionally matched controls.
Validation phase samples. Finnish population matched
cases (n = 954) were selected from a population-based material of
1,042 CRC patients [4,18] and from an additional series of 472
Finnish CRC cases, based on DNA availability. The control DNA
samples (n = 586) were from population matched healthy individ-
uals and obtained from the Finnish Red Cross Blood Transfusion
Service.
Exome sequencing
The Agilent SureSelect Human All Exon Kit v1 (Agilent, Santa
Clara, CA, USA) was used to capture exomic regions. Paired end
short reads were sequenced on either Illumina GAII or HiSeq
platform (Illumina Inc., San Diego, CA, USA). Raw sequence data
was received in FASTQ format and quality checked with FASTQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). All exomes
passed the quality control. 39 ends with high adapter similarity were
removed by an in-house script whereafter reads were mapped to the
human reference genome GRCh37 by BWA (Burrow-Wheelers
Aligner). Duplicates were removed with Picard Tools (http://picard.
sourceforge.net) MarkDuplicates. Local realignment was done by
Genome Analysis Toolkit (GATK) IndelRealigner to improve the
detection of small insertions and deletions. The initial single
nucleotide variant (SNV) and indel calls needed for creating the
GATK realignment intervals were made using samtools mpileup and
downloaded from the 1000 genomes project Phase I indel calls
([16]the August 2010 release). Final SNV and indel calls were made
using the GATK UnifiedGenotyper with a low variant quality score
threshold (1.0).
Exome data analysis
Exome data analysis was performed in ‘‘Rikurator’’, an in-house
visualization and comparative analysis tool (unpublished). The tool
allowed for simultaneous analysis of all the 96 exomes and
interactive quality/control filtering. The following quality filters
were used: (i) variants had to have a quality score $50, (ii)
coverage had to be $6, and (iii) the percentage of mutated reads
had to be $30. Truncating variants, including nonsense,
frameshifting insertion and deletion, or splice-site alteration IVS
+1, +2, 21, and 22, were extracted. Data was control filtered
against population matched exome control data (n = 212) and data
from the 1000 Genomes Project (Phase 1 release) [16]. Variants
were excluded if present in the 1000 Genomes Project or exome
control data at MAF.0.001 (Figure 1). Genes with truncating
variants present in at least 2/96 cases were studied further.
Manual filtering was performed on all variants to further remove
artifacts due to duplicated regions, mapping errors, and systematic
errors. Systematic errors, both position specific and sequence
specific, in high-throughput sequence data have been described
previously by Meacham et al [26]. Finally, outputs were generated
for Ensembl canonical transcripts (Ensembl build 37).
Sanger validation of the exome findings
Potential loss-of-function variants were verified by Sanger
sequencing from DNA extracted from normal tissue samples.
Sequencing primers were designed with the Primer3-program
(http://frodo.wi.mit.edu/primer3/) using NCBI37/Hg19 as the
reference sequence. The primer sequences can be found in Text
S1. The fragments were amplified with the AmpliTaqGold
enzyme (Applied Biosystems, Foster City, CA). The PCR products
were purified using the ExoSAP-IT PCR purification kit (USB
Corporation, Cleveland, OH, USA). Electrophoresis was run on a
3730xl DNA Analyzer (Applied Biosystems at Institute for
Molecular Medicine Finland, FIMM). The sequencing reactions
were performed utilizing the Big Dye Terminator v.3.1 kit
(Applied Biosystems, Foster City, USA), Sanger sequencing was
performed implementing the ABI31006l technology (Applied
Figure 2. Examples of DNA sequence chromatograms. Chro-
matograms on the top demonstrate c.3346C.T, p.Q1116X in UACA.
Chromatograms on the bottom demonstrate c.121C.T, p.Q41X in
TWSG1. DNA extracted from tumor tissue shows LOH with retention of
the mutated alleles (right). The wild-type alleles can still be seen in the
tumor chromatograms, due to normal tissue contamination in the
tumor samples.
doi:10.1371/journal.pgen.1003876.g002
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Biosystems), and the sequence graphs were visualized with the
Chromas – software (version 2.33, Technelysium Pty Ltd,
Helensvale, Australia). The results were analyzed both manually
and with the Mutation Surveyor –software (version v3,30,
Softgenetics, State College, PA, USA). Confirmed truncating
variants were Sanger sequenced in 310 Finnish population
matched healthy controls, of whom about two-thirds were
regionally matched. Sanger sequencing was performed as
described above. All variants that had a MAF.0.001 in the
discovery phase control set were excluded.
Loss of heterozygosity analysis
Sanger sequencing was also performed on DNA extracted from
tumor tissue in cases carrying validated truncating variants. All
tumors had been microscopically evaluated by a pathologist and
all except one contained $50% of carcinoma tissue. Loss of
heterozygosity was analyzed by comparing allelic ratios of tumor
and respective normal tissue DNA, as previously described [27].
Peak heights were manually measured from sequence graphs
based on which allelic ratios were calculated.
Genotyping of population matched cases and controls
Variants in genes showing loss of the wild-type allele in tumor
tissue were genotyped in a set of validation phase samples,
comprising 954 population matched CRC cases and 586
population matched controls. Genotyping was carried out by
using the 7900HT Fast Real-Time PCR System (Applied
Biosystems) and was performed at the Estonian Genome Center,
University of Tartu. The variant p.Q41X in TWSG1 was
genotyped using massARRAY iPLEX Gold (Sequenom, San
Diego, CA) and performed at the Institute for Molecular Medicine
Finland (FIMM), University of Helsinki. The genotyping condi-
tions and primers utilized can be found in Text S1. Genotyping
success rates were over 90% for all the variants, except for PSPH
where the genotyping assay failed. All the variants identified by
genotyping were further confirmed by Sanger sequencing.
Missense variants at candidate CRC loci
The exome data was searched for missense variants at the 11
candidate predisposition loci. The same filtering criteria were
utilized as for truncating variants. The variants were excluded if
present in Exome Variant Server (NHLBI GO Exome Sequencing
Project (ESP), Seattle, WA, http://evs.gs.washington.edu/EVS/
[July 2013]) with MAF.0.001. The functional effects of the
identified missense variants were predicted by SIFT (http://sift.jcvi.
org/) and PolyPhen 2 (http://genetics.bwh.harvard.edu/pph2/).
Segregation of truncating variants
Archived Formalin-fixed, Paraffin-embedded (FFPE) tissue
samples were ordered for first degree relatives with CRC
Figure 3. Pedigrees of families found to carry UACA and TWSG1 truncating variants. Carrier status is depicted for all the cases for whom
readily extracted DNA was available. The individuals that underwent exome sequencing are marked with an arrow. Numbers represent the age at
diagnosis of the affected individuals. The following abbreviations are used: CRC, colorectal cancer; BCC, basal cell carcinoma, MG, meningioma; HD,
Hodgkin lymphoma; PC, prostate cancer; MM, melanoma and LC, lung cancer.
doi:10.1371/journal.pgen.1003876.g003
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whenever possible. Genomic DNA was extracted from all available
FFPE samples. Sanger sequencing was performed on identified
truncating variants to test for segregation. In total, segregation was
analyzed in seven families for five of the identified truncating
variants.
Statistics
One-tailed exact binominal test was used for P-value calcula-
tions.
Supporting Information
Figure S1 Pedigrees of families with truncating variants in
ZNF490, SFXN4, PRADC1, and AKRIC4, in which segregation
analysis was carried out. The individuals that underwent exome
sequencing are marked with an arrow. Carrier status is depicted
for all the CRC cases. Numbers represent the age at diagnosis of
the affected individuals. The following abbreviations are used:
CRC, colorectal cancer; BCC, basal cell carcinoma; GC, gastric
cancer; G, glioma; HD, hodgkin lymphoma; PC, prostate cancer;
MM, melanoma and LC, lung cancer.
(TIF)
Table S1 Clinical information on the 96 familial colorectal
cancer cases exome sequenced.
(XLS)
Table S2 Gene description and proposed gene function of the
identified candidate CRC predisposing genes.
(XLS)
Table S3 Missense variants at candidate CRC predisposition
loci.
(DOC)
Text S1 PCR primers utilized in the Sanger validation of the
variants, genotyping conditions and primers utilized in genotyping.
(DOCX)
Acknowledgments
We thank Sini Nieminen, Sirpa Soisalo, Inga-Lill Svedberg, Iina Vuoristo,
Alison Ollikainen and Sini Karjalainen for excellent technical assistance.
We also thank the staff at the Finnish Institute of Molecular Medicine
(FIMM) Genome and Technology Center and the Estonian Genome
Center, University of Tartu. We acknowledge professor Aarno Palotie
(FIMM and Wellcome Trust Sanger Institute, UK) and docent Maija
Wessman (FIMM and Folkha¨lsan Research Center, Helsinki) for providing
Finnish, population-specific exome sequences for filtering.
Author Contributions
Conceived and designed the experiments: AEG JK OK EP PV ST AK
LAA. Performed the experiments: AEG RK JK TT TC UH OK.
Analyzed the data: AEG RK TC. Contributed reagents/materials/analysis
tools: JT MT LRS HJ JPM. Wrote the paper: AEG AK LAA. Planned and
designed the study: AEG PV ST OK AK LAA. Performed the exome
sequencing: JT MT. Developed exome analysis tools: RK EP. Analyzed
the exome data: RK AEG. Validated the exome findings: AEG JK TT TC
UH. Performed additional genetic screens: AEG TC. Provided study
samples: LRS HJ JPM.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
2. American Cancer Society (2013) Cancer Facts & Figures 2013. Available:
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-036845.pdf. Accessed 26 July 2013.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000)
Environmental and heritable factors in the causation of cancer–analyses of
cohorts of twins from sweden, denmark, and finland. N Engl J Med 343: 78–85.
4. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, et al. (1998)
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of
molecular screening for the disease. N Engl J Med 338: 1481–1487.
5. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, et al. (2012)
Germline mutations affecting the proofreading domains of POLE and POLD1
predispose to colorectal adenomas and carcinomas. Nat Genet 45: 136–144.
6. Pearson P, Francomano C, Foster P, Bocchini C, Li P, et al. (1994) The status of
online mendelian inheritance in man (OMIM) medio 1994. Nucleic Acids Res
22: 3470–3473.
7. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, et al. (1997) Familial
colorectal cancer in ashkenazim due to a hypermutable tract in APC. Nat Genet
17: 79–83.
8. Cleary SP, Zhang W, Di Nicola N, Aronson M, Aube J, et al. (2003) Heterozygosity
for the BLM(ash) mutation and cancer risk. Cancer Res 63: 1769–1771.
9. Guda K, Moinova H, He J, Jamison O, Ravi L, et al. (2009) Inactivating germ-
line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12
in human colon cancers. Proc Natl Acad Sci U S A 106: 12921–12925.
10. Lubbe SJ, Di Bernardo MC, Broderick P, Chandler I, Houlston RS. (2012)
Comprehensive evaluation of the impact of 14 genetic variants on colorectal
cancer phenotype and risk. Am J Epidemiol 175: 1–10.
11. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, et al. (2012)
Common variation near CDKN1A, POLD3 and SHROOM2 influences
colorectal cancer risk. Nat Genet 44: 770–776.
12. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, et al. (2013)
Cumulative impact of common genetic variants and other risk factors on
colorectal cancer risk in 42,103 individuals. Gut 62: 871–881.
13. Niittymaki I, Kaasinen E, Tuupanen S, Karhu A, Jarvinen H, et al. (2010) Low-
penetrance susceptibility variants in familial colorectal cancer. Cancer Epidemiol
Biomarkers Prev 19: 1478–1483.
14. Peltonen L, Palotie A, Lange K. (2000) Use of population isolates for mapping
complex traits. Nat Rev Genet 1: 182–190.
15. Jakkula E, Rehnstrom K, Varilo T, Pietilainen OP, Paunio T, et al. (2008) The
genome-wide patterns of variation expose significant substructure in a founder
population. Am J Hum Genet 83: 787–794.
16. Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo
MA, et al (2012) An integrated map of genetic variation from 1,092 human
genomes. Nature 491: 56–65.
17. Ku CS, Naidoo N, Pawitan Y. (2011) Revisiting mendelian disorders through
exome sequencing. Hum Genet 129: 351–370.
18. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, et al. (2000)
Population-based molecular detection of hereditary nonpolyposis colorectal
cancer. J Clin Oncol 18: 2193–2200.
19. Fletcher O, Houlston RS. (2010) Architecture of inherited susceptibility to
common cancer. Nat Rev Cancer 10: 353–361.
20. Bodmer W, Bonilla C. (2008) Common and rare variants in multifactorial
susceptibility to common diseases. Nat Genet 40: 695–701.
21. Gibson G. (2012) Rare and common variants: twenty arguments. Nat Rev Genet
13: 135–145.
22. Liu L, Sakai T, Sano N, Fukui K. (2004) Nucling mediates apoptosis by
inhibiting expression of galectin-3 through interference with nuclear factor
kappaB signalling. Biochem J 380: 31–41.
23. Moravcikova E, Krepela E, Prochazka J, Rousalova I, Cermak J, et al. (2012)
Down-regulated expression of apoptosis-associated genes APIP and UACA in
non-small cell lung carcinoma. Int J Oncol 40: 2111–2121.
24. Chang C, Holtzman DA, Chau S, Chickering T, Woolf EA, et al. (2001) Twisted
gastrulation can function as a BMP antagonist. Nature 410: 483–487.
25. Tzachanis D, Li L, Lafuente EM, Berezovskaya A, Freeman GJ, et al. (2007)
Twisted gastrulation (tsg) is regulated by tob and enhances TGF-beta signaling
in activated T lymphocytes. Blood 109: 2944–2952.
26. Meacham F, Boffelli D, Dhahbi J, Martin DI, Singer M, et al. (2011)
Identification and correction of systematic error in high-throughput sequence
data. BMC Bioinformatics 12: 451-2105-12-451.
27. Tuupanen S, Niittymaki I, Nousiainen K, Vanharanta S, Mecklin JP, et al.
(2008) Allelic imbalance at rs6983267 suggests selection of the risk allele in
somatic colorectal tumor evolution. Cancer Res 68: 14–17.
Novel Susceptibility Genes for Colorectal Cancer
PLOS Genetics | www.plosgenetics.org 8 October 2013 | Volume 9 | Issue 10 | e1003876
